DiaMedica schedules Oct. 23 webinar to present interim Phase 2 early-onset fetal growth restriction data for DM199

By Public Technologies
  • DiaMedica Therapeutics set an Oct. 23, 2026 virtual KOL webinar on DM199 in early-onset fetal growth restriction.
  • Early interim topline findings from the first Phase 2 cohort were already generated, with safety and initial trial observations to be presented.
  • Enrollment finished for the first cohort; dosing has started in the second cohort, marking the first use of DM199 in early-onset FGR.
  • Management framed the initial readout as supporting further evaluation of DM199 as a potential treatment option in FGR.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300830BIZWIRE_USPR_____20260930_BW867672) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.